Small and medium-sized enterprises (SMEs) are often faced with the challenge of having limited resources which can impact their ability to seamlessly move products through the pipeline from clinical development to launch and post-marketing activities. This is further exacerbated by the growing complexity of regulatory requirements and significant pressure companies face to get their products to market as quickly as possible – balancing these two requirements can be virtually impossible. In this white paper, Dr Chitra Lele, Chief Scientific Officer at Sciformix Corporation, looks into the safety and regulatory solutions at biopharmaceutical companies.